|drug3511||Training video on anxiety, fear and loneliness in the COVID-19 environment. Wiki||0.58|
|drug1731||Investigation of smell and taste disorders Wiki||0.58|
|D000857||Olfaction Disorders NIH||0.14|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
There are 3 clinical trials
A novel coronavirus SARS-CoV-2 HAS arose in 2019 in Wuhan, China. Beside the classical semiology of this infection, numerous patients described olfactory and teste disorders. These symptoms are not described in this coronavirus, neurotropism of coronaviridae has been documented before. The aim of the study is to evaluate prevalence of anosmia and dysgeusia (olfactory and taste disorders) in coronavirus diagnosed patients and compare with different clinical conditions. The second endpoint is to evaluate the duration of these symptoms in order to better understand the semiology of this infection.
Description: Prevalence for anosmia in the COVID-19 + patientsMeasure: Anosmia Time: 45 days
Description: Prevalence for ageusia in the COVID-19 + patientsMeasure: Ageusia Time: 45 days
Description: Duration measured in daysMeasure: Duration of the loss of anosmia ageusia Time: 45 days
This is a prospective monocentric observational study with the aim of investigating the demographic and clinical factors related to the smell and taste disorders in patients with Severe Acute Respiratory Syndrome - Coronavirus - 2 (Sars-Cov-2) infection.
Description: Identify the demographic and clinical factors related to the sense of smell and taste in patients with Sars-CoV-2 infection included in the study.Measure: Identification of demographic and clinical factors in covid19 patients. Time: Until patient discharge from the hospital (approximately four months)
Description: Description in patients with Sars-CoV-2 infection the evolution of the symptoms (disturbances of smell and taste) understood as partial or total regression by 1-month and 3-month follow-upMeasure: Description of the disturbances of smell and taste Time: Until patient discharge from the hospital (approximately four months)
Description: Define which factors (demographic and clinical) influence the improvement of the sense of smell and tasteMeasure: Description of factors that influence smell and taste Time: Until patient discharge from the hospital (approximately four months).
Evaluating the smell and taste perceptions of patients hospitalized in the intensive care unit with suspicion of Coronavirus disease-19 diagnosis with a survey study
Description: incidence of taste and smell impairment in critically ill subjectsMeasure: taste and smell impairment Time: up to 3 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports